Over the past few years, incidental thyroid microcarcinoma has become a frequent disease, and its reported incidence is considerable. Discovering new cases depends on the extended indications for total thyroidectomy for benign disease, on progress in the field of diagnostic instruments (ultrasound, scintigram, fine needle biopsy for cytology, CT scan, MRI, PET), and on the pathological examination of very thin slices of specimens. In spite of the high incidence reported in some autopsy series, which suggests that this tumour may have a good prognosis, some Authors report an overall incidence of up to 11% of local recurrence, metastasis or mortality. For all these reasons, the surgical treatment of incidental thyroid microcarcinoma is still controversial. The aim of this study was to estimate the prevalence of incidental thyroid microcarcinoma and examine the clinical-pathological findings of incidental thyroid microcarcinoma. A total of 199 operative findings derived from total thyroidectomy that were recorded between January 2012 and December 2015 were assessed from the point of view of a histopathology. The histological diagnosis was made by a pathologist according to the recommendations of the World Health Organization (WHO) through an assessment of sections of the thyroid gland that were no more than 2 mm thick. Following these routine histological examinations, 28 cases (14,07%) of "incidental" thyroid microcarcinoma were found. The mean tumour size was 4.10 mm (range: 0.12 mm to 10 mm). The tumours were multifocal in two patients, and none of them presented lymph node metastases. Thyroid microcarcinoma is a malignant tumour associated with a good prognosis. Multifocality should be the main factor considered in selecting the type of thyroid surgery. A total thyroidectomy may be regarded as sufficient treatment for this condition.
Introduction
The definition of "microcarcinoma" is attributed to any thyroid neoformation that has a maximum diameter of less than 1 cm. Traces of microcarcinoma are usually found incidentally in case of histological examination performed on surgery or autopsy findings carried out for not neoplastic pathologies (1) (2) (3) . Morphology histology, also the medullary carcinoma can appear as microcarcinoma; i.e., with incidental localizations of dimensions that are smaller than 1 cm (4) . But the type histology that is most commonly detected is the papillary. It is a widely held opinion that the abutment of microcarcinoma does not give a big help on the evaluation of patient's prognosis; it is still controversial, however, the value of a surgical and perhaps radical therapy to solve the case (5, 6) . On the basis of this, we considered it appropriate to analyse the clinical significance of incidental microcarcinoma in our personal experience relating to 199 total thyroidectomies that were performed for benign disorders of the thyroid between January 2012 and December 2015 according to an uniform diagnostic criterion. The analysis of existing literature on the subject and our experience have led us to some considerations under the methodological and clinical point of view.
Materials and Methods
Between January 2012 and December 2015, 199 thyroidectomies for benign diseases of the thyroid were carried out, all of which met the methodological criteria of homogeneity with regard to histopathological studies. In all cases, the surgery involved total thyroidectomies as planned, according to the indications currently described in the literature (7, 8) . The tissues were preserved in formalin and after weighed and measured the maximum diameters of the neoplastic nodule (9) . The gland was then oriented and sectioned on a coronal plane transverse 0 at distances of 2 mm. The cutting surface was examined and any suspected lesions placed on a glass slide for histological examination together with some tissue apparently unscathed. After colouring with hematoxylin-eosin, the diagnostic criteria proposed by Zampi and Rosai (10) was employed (Table 1) , which is essentially based on a combination of architectural and cytological criteria that are as follows (in order of relevance): 1. nuclear characteristics 2. cytoplasmic characteristics 3. architectural characteristics.
Results
In 28 cases (14.07%) there were traces of microcarcinoma. All of these cases involved women who were aged between 23 and 80 years. The diameter of these findings ranged from 0.12 to 1 cm. In 9 cases, there was an infiltrated nature, in 2 cases the outbreaks were multicentre, metastatic lymph nodes were not present in any cases ( Table 2 ). The morphological features detected were as follows: absence of the capsule in the neoformation of less than 3 mm diameter and a prevalence of follicular forms under 4 mm, this ratio is reversed in neoformation from half a centimetre diameter and more.
Discussion
The thyroid microcarcinoma is a clinical identity of difficult nosological classification. According to the definition provided by the WHO, a micro thyroid carcinoma is a malignant tumour of a diameter that does not exceed 10 mm (11), but it can have different sizes and forms, the tiny form with a diameter of between 5 and 10 mm and the minute with a diameter of less than 5 mm (12) . The microcarcinoma of the thyroid can be diagnosed as "incidentaloma" after thyroidectomy for benign diseases to which it often associates; or as "occult carcinoma" when lymph node metastases exist even if the thyroid seems unscathed. Finally, a "latent carcinoma" is found only at the point of a post-mortem examination. Currently, the number of microcarcinoma reported in the literature is increasing at a significant rate (13, 14) , both for the increasingly accuracy of the surgical techniques used, and for the attention with which these neoplasms are seek by the histologist also in thyroid disease hyperplasia (15) . The incidence of microcarcinoma is 7-16% of all malignant tumours of the thyroid; it can occur in patients of all ages, and it has a F-M ratio of 3:1. From an epidemiological perspective, there is a difference between the remarks of microcarcinoma arising from autopsy studies and those based on incidental findings in the course of the surgical intervention. In the first case, the frequency is higher in males and is constant across the various classes of age. There is no report that outlines specific thyroid pathologies. In our experience, micro incidental carcinoma exclusively affects female patients with median age of 44 years, all of whom are subject to intervention for thyroid disease supposed hyperplasia (Table 3) . In our experience with regard to morphological aspects (Table 2 ), a histological pattern that is definable as a "classic" papillary is prevalent with respect to the definition of "follicular variety of papillary". There is a lack of knowledge available about the molecular changes involved in the development of the papillary microcarcinoma. The existing biological research is moving to the direction of the investigations on the molecular alterations most frequently found in papillary carcinoma thyroid not occult, such as the RET proto-oncogene, which is mapped in the long arm of chromosome 10 at band q 11.2 (16). This gene encodes a receptor tyrosine kinase the expression and function of which are normally reserved for a group of cells derived from the neural crest. The activation of the RET oncology gene in papillary carcinoma occurs for chromosomal rearrangement resulting in the melting of the region encoding the RET tyrosine kinase with the region encoding amino-terminal. The hypothesis that the microcarcinoma might represent an early stage of the papillary carcinoma has been commonly cited in the literature (17) . However, only a small part of the microcarcinoma seems to then evolve into a "mature" papillary carcinoma and this is the source of the controversy concerning the optimal therapeutic strategy. Therefore, the possible role of the RET in the appearance of microcarcinomas was investigated to establish if the rearrangement of the RET can serve as an useful marker for a prognosis. From a clinical and surgical point of view, the above considerations regarding both the biological behaviour and the course of this pathology suggest a nature that cannot be defined as neoplastic classically. The prognosis of patients is basically hyperplasia, therefore some Authors confirm that the lobectomy is the surgical therapy of choice and additional treatments are not indicated (18) . In our experience, this is, in all cases of patients gone for a total thyroidectomy, the indication of which was placed in principle in the presence of benign thyroid diseases and then performed to control the "metabolic" of the underlying disease. There is a difference between the literature data on autopsy locators (18) and our experience. We have found that the highest incidence occurs in patients who are suffering from thyroid nodules: this is an evolutionary disease with proliferative stimulus supported by growth factors different from TSH and alterations in the intrinsic cell thyroid. At the present, acquisitions on natural history and derived characteristics classifies the microcarcinoma as a simple post surgery pathological trace (19) . Its biological significance remains controversial since it is not known if the thyroid microcarcinoma represents the very early stage of a neoplasia that is destined to develop in time and grow at a more or less rapid rate. The consideration above related to poor clinical interest of the lesion, the prognosis of which remains absolutely favourable, was, and remains, the basis of the different surgical approaches proposed in accordance with the degree of extension of the thyroidectomy: lobectomy or total thyroidectomy (20, 21) . However, in reality, the aforementioned dispute appears devoid of fundamental consistency. From the clinical point of view, it is evident that MCT exhibits different biological behaviour and a different natural history than "mature" papillary carcinoma, corresponding to a situation of benignity. A total thyroidectomy, as carried out in principle in the presence of benign thyroid diseases is, therefore, a sufficient therapy for the treatment of thyroid microcarcinoma.
